BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alumis readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Alumis's drugs run\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05739435-1803@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Envudeucitinib: Phase 2 readout est. (NCT05739435)
DESCRIPTION:Envudeucitinib\, phase 2\, Psoriasis.\nStudy: Open-Label Extens
 ion Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaq
 ue Psoriasis\nEstimated primary completion: 1 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/envudeucitinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05739435
URL:https://assetmemo.bio/drug/envudeucitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846541-1803@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Envudeucitinib: Phase 3 readout est. (NCT06846541)
DESCRIPTION:Envudeucitinib\, phase 3\, Psoriasis.\nStudy: Long-term Safety 
 and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis\nEstimated 
 primary completion: November 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/envudeucitinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06846541
URL:https://assetmemo.bio/drug/envudeucitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
